Elemer Piros
Stock Analyst at LUCID CAPITAL MARKETS
(2.85)
# 978
Out of 5,182 analysts
90
Total ratings
35.71%
Success rate
10.98%
Average return
Main Sectors:
Stocks Rated by Elemer Piros
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INMB INmune Bio | Upgrades: Buy | $2 → $9 | $1.54 | +484.42% | 1 | Mar 11, 2026 | |
| XOMA XOMA Royalty | Initiates: Buy | $76 | $41.66 | +82.43% | 1 | Dec 9, 2025 | |
| BTAI BioXcel Therapeutics | Reiterates: Buy | $66 | $1.25 | +5,180.00% | 2 | Jul 15, 2025 | |
| FBLG FibroBiologics | Initiates: Buy | $240 | $1.33 | +17,945.11% | 1 | Dec 12, 2024 | |
| QNCX Quince Therapeutics | Initiates: Buy | $110 | $1.23 | +8,843.09% | 1 | Oct 29, 2024 | |
| MNPR Monopar Therapeutics | Initiates: Buy | $50 | $56.88 | -12.10% | 6 | Oct 11, 2024 | |
| MIRA MIRA Pharmaceuticals | Initiates: Buy | $17 | $1.02 | +1,566.67% | 1 | Sep 30, 2024 | |
| CGTX Cognition Therapeutics | Reiterates: Buy | $14 | $1.24 | +1,029.03% | 1 | Jul 2, 2024 | |
| ANVS Annovis Bio | Reiterates: Buy | $67 | $2.27 | +2,851.54% | 1 | Jul 2, 2024 | |
| ANRO Alto Neuroscience | Initiates: Buy | $43 | $25.45 | +68.96% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $4.25 | +323.53% | 7 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7.5 | $0.71 | +956.34% | 3 | Sep 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $4.00 | +275.00% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $9.32 | +307.73% | 9 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $0.85 | +4,605.88% | 2 | Jul 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $8.08 | +518.81% | 5 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $200 | $6.58 | +2,939.51% | 6 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $33 | $21.28 | +55.08% | 3 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $40 | $40.97 | -2.37% | 7 | Apr 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $0.25 | +14,466.93% | 1 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $32 | $6.25 | +412.00% | 2 | Jun 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $77 | $8.41 | +815.58% | 2 | Dec 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $10.67 | - | 5 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $50 | $74.93 | -33.27% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $33 | $1.72 | +1,818.60% | 2 | Oct 22, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $14.77 | +76.03% | 3 | May 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $284.57 | -90.16% | 1 | Sep 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $525 → $850 | $5.83 | +14,479.76% | 1 | Oct 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $21 | $9.71 | +116.27% | 2 | Jul 12, 2017 |
INmune Bio
Mar 11, 2026
Upgrades: Buy
Price Target: $2 → $9
Current: $1.54
Upside: +484.42%
XOMA Royalty
Dec 9, 2025
Initiates: Buy
Price Target: $76
Current: $41.66
Upside: +82.43%
BioXcel Therapeutics
Jul 15, 2025
Reiterates: Buy
Price Target: $66
Current: $1.25
Upside: +5,180.00%
FibroBiologics
Dec 12, 2024
Initiates: Buy
Price Target: $240
Current: $1.33
Upside: +17,945.11%
Quince Therapeutics
Oct 29, 2024
Initiates: Buy
Price Target: $110
Current: $1.23
Upside: +8,843.09%
Monopar Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $50
Current: $56.88
Upside: -12.10%
MIRA Pharmaceuticals
Sep 30, 2024
Initiates: Buy
Price Target: $17
Current: $1.02
Upside: +1,566.67%
Cognition Therapeutics
Jul 2, 2024
Reiterates: Buy
Price Target: $14
Current: $1.24
Upside: +1,029.03%
Annovis Bio
Jul 2, 2024
Reiterates: Buy
Price Target: $67
Current: $2.27
Upside: +2,851.54%
Alto Neuroscience
Jun 21, 2024
Initiates: Buy
Price Target: $43
Current: $25.45
Upside: +68.96%
Jun 13, 2024
Initiates: Buy
Price Target: $18
Current: $4.25
Upside: +323.53%
Sep 14, 2023
Maintains: Buy
Price Target: $12 → $7.5
Current: $0.71
Upside: +956.34%
Aug 9, 2023
Reiterates: Buy
Price Target: $15
Current: $4.00
Upside: +275.00%
Aug 3, 2023
Reiterates: Buy
Price Target: $38
Current: $9.32
Upside: +307.73%
Jul 10, 2023
Reiterates: Buy
Price Target: $40
Current: $0.85
Upside: +4,605.88%
Jun 30, 2023
Reiterates: Buy
Price Target: $50
Current: $8.08
Upside: +518.81%
Jun 20, 2023
Maintains: Buy
Price Target: $260 → $200
Current: $6.58
Upside: +2,939.51%
Mar 2, 2023
Reiterates: Buy
Price Target: $33
Current: $21.28
Upside: +55.08%
Apr 14, 2022
Downgrades: Sell
Price Target: $40
Current: $40.97
Upside: -2.37%
Dec 1, 2021
Initiates: Buy
Price Target: $37
Current: $0.25
Upside: +14,466.93%
Jun 30, 2021
Maintains: Buy
Price Target: $38 → $32
Current: $6.25
Upside: +412.00%
Dec 23, 2020
Downgrades: Sell
Price Target: $77
Current: $8.41
Upside: +815.58%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $10.67
Upside: -
Nov 19, 2019
Maintains: Neutral
Price Target: $24 → $50
Current: $74.93
Upside: -33.27%
Oct 22, 2019
Assumes: Overweight
Price Target: $33
Current: $1.72
Upside: +1,818.60%
May 6, 2019
Initiates: Overweight
Price Target: $26
Current: $14.77
Upside: +76.03%
Sep 11, 2018
Initiates: Overweight
Price Target: $28
Current: $284.57
Upside: -90.16%
Oct 12, 2017
Maintains: Overweight
Price Target: $525 → $850
Current: $5.83
Upside: +14,479.76%
Jul 12, 2017
Maintains: Overweight
Price Target: $35 → $21
Current: $9.71
Upside: +116.27%